LRMR Insider Trading

Insider Ownership Percentage: 3.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Larimar Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Larimar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Larimar Therapeutics Share Price & Price History

Current Price: $2.00
Price Change: Price Decrease of -0.15 (-6.98%)
As of 04/1/2025 05:00 PM ET

This chart shows the closing price history over time for LRMR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$2.15Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Larimar Therapeutics (NASDAQ:LRMR)

91.92% of Larimar Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at LRMR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$5.87Mbought$3.81MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Larimar Therapeutics logo
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
Read More on Larimar Therapeutics

Today's Range

Now: $2.00
Low: $1.96
High: $2.12

50 Day Range

MA: $3.05
Low: $2.15
High: $3.97

52 Week Range

Now: $2.00
Low: $1.98
High: $11.20

Volume

927,899 shs

Average Volume

647,751 shs

Market Capitalization

$128.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Who are the company insiders with the largest holdings of Larimar Therapeutics?

Larimar Therapeutics' top insider shareholders include:
  1. James E Flynn (Director)
  2. Michael Celano (CFO)
  3. Joseph Truitt (Director)
  4. Frank E Thomas (Director)
Learn More about top insider investors at Larimar Therapeutics.